We use cookies to improve your browsing experience on our website.
Please visit our Privacy Notice for more information about cookies and how we use them. We recommend that you accept the use of cookies for better navigation.

PROMOGRAN™ Protease Modulating Matrix

Products described on this website (and associated product information), may not be available for sale in all markets as a result of local regulatory requirements. For information regarding product availability in your market, please contact your local Acelity/KCI representative here.

A Clinically Proven Combination

PROMOGRAN™ Protese Modulating Matrix is comprised of a sterile, freeze dried composite of 45% oxidized regenerated cellulose (ORC) and 55% collagen.

 

Optimum Wound Environment

PROMOGRAN™ Matrix maintains an optimal wound healing environment. This environment is conducive to granulation tissue formation, epithelization and rapid wound healing. 

 

Specific indications, contraindications, warnings, precautions and safety information exist for KCI products and therapies. Healthcare providers should review the product User Manual, Safety Information and/or Instructions for Use prior to application.

 

 


  • Overview
  • How it Works
  • Indications & Applications
  • Evidence & Outcomes
  • Ordering

    Overview

Clinically Proven

PROMOGRAN™  Dressing COLLAGEN & ORC is supported by a body of clinical evidence, including 13 RCT's data.1-13

Several RCT's have demonstrated that PROMOGRAN™ Protease Modulating Dressing achieved superior results versus standard of care in chronic wounds.

Economic Value

 

PROMOGRAN™  Dressing was more cost-effective per patient over 6 weeks of treatment as compared to standard care (Control).3

KCI Advanced Wound Dressings Advanced Dressing Technology

 

PROMOGRAN™ Matrix Family, the only dressings with callogen and Oxidized Regenerated Cellulose (ORC).

How it Works

  • ABOUT
  • SPECIFICATIONS

Maintains an optimum wound healing environment

In the presence of exudate, PROMOGRAN™  Matrix transforms into a soft, conformable, biodegradable gel. This allows contact with all areas of the wound.
 
 
Economic Value

An additional retrospective study analyzing cost-effectiveness in the management of neuropathic DFU (n=40), showed that wound Management with PROMOGRAN™  Matrix was more cost-effective per patient over 6 weeks of treatment as compared to standard care (Control).3

Product Description

PROMOGRAN™ Matrix is a topically applied interactive wound therapy. The product is a sterile, freeze dried composite of oxidised regenerated cellulose (ORC) and collagen. In the presence of exudate the PROMOGRAN™ Matrix transforms into a soft conformable, biodegradabile gel; this allows contact with all areas of the wound. Saline or Ringer's solution should be used to rehydrate PROMOGRAN™ Matrix on dry wounds.

 

PROMOGRAN™ Matrix modulates and re-balances the wound environment by the unique combination of:

  1.    1. Binding and inactivation of proteases (i.e. matrix metallo proteases, elastase and plasmin) which have been shown to be detrimental in excess chronic wounds
  2.    2. Binding and protection of naturally occurring growth factors against degradation by these excecess proteases

The naturally occurring, protected growth factors are released back into the wound, while the detrimental proteases remain upon bio-degradation of the PROMOGRAN™ Matrix. PROMOGRAN™ Matrix has demonstrated free radical scavenging properties. 

PROMOGRAN-Matrix-Specs.png

Indications & Applications

  • INDICATIONS
  • APPLICATIONS

Specific indications, contraindications, warnings, precautions and safety information exist for KCI products and therapies. Healthcare providers should review the product User Manual, Safety Information and/or Instructions for Use prior to application.

 

Indications for use

PROMOGRAN™ Matrix is intended for the management of all wounds healing by secondary intent which are clear of necrotic tissue, including::

  • Diabetic ulcers
  • Venous ulcers
  • Pressure ulcers
  • Ulcers caused by mixed vascular aetiologies
  • Traumatic and surgical wounds
  • PROMOGRAN™ Matrix can be used under compression therapy

 

Contraindications

PROMOGRAN™ Matrix is contraindicated in patients with known hypersensitivity to the components of this product, i.e. ORC and Collagen. Discontinue use if signs of sensitivity appear. 

Wound Bed Preparation
Prepare wound bed per your standard wound care protocol and debride when necessary. Wound bed should be clear of any visual signs of infection. 

 

Application

  • For optimal effect, apply PROMOGRAN™ Matrix directly to the whole wound bed.
  • For a wound with low or no exudate apply PROMOGRAN™ Matrix and hydrate with saline solution. This will initiate the transformation of the PROMOGRAN™ Dressing into a gel matrix.
  • After hydration, through exposure to wound exudate or saline, the PROMOGRAN™ Matrix gel will intimately come into contact with the wound surface.
  • The biodegradable PROMOGRAN™ gel matrix is naturally absorbed into the body over time.
  • In order to maintain a moist wound healing environment PROMOGRAN™ Matrix must be covered with a semi-occlusive dressing (e.g. BIOCLUSIVE™  Plus Transparent Film Dressing, TIELLE™  Hydropolymer Foam Dressings or TIELLE™  Plus Hydropolymer Adhesive Dressing) or a non-occlusive secondary dressing and fixed to the skin with a non-irritating tape.
  • After initial application, reapply PROMOGRAN™ Matrix to the wound up to every 72 hours depending upon the amount of exudate. It is not necessary to remove any residual PROMOGRAN™ Matrix during dressing changes. 

 

 

Evidence & Outcomes

 

The efficacy of PROMOGRAN™ Matrix is supported by clinical evidence, including 13 published RCTs.1Acelity Clinical Evidence is a resource for healthcare professionals to explore clinical, and review articles discussing the use of Acelity™  products. 

Clinical Evidence

Additional summary of evidence and outcomes.
TITLE Wound conditioning of a deep tissue defect including exposed bone after tumour excision using PROMOGRAN* Matrix, a protease-modulating matrix.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2005
AUTHORS Tausche AK, et al.
TITLE Collagen ORC rebalances the wound environment
View Abstract on PubMed
STUDY TYPE All levels
DATE 2003
AUTHORS Cullen B, et al.
TITLE Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2006
AUTHORS Lobmann R, et al.
TITLE The healing properties of Promogran in venous leg ulcers.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Vin F, et al.
TITLE Expression of Matric-Metalloproteases in the Fluid of Chronic Diabetic Foot Wounds Treated with a Protease Absorbent Dressing
View Abstract on PubMed
STUDY TYPE All levels
DATE 2011
AUTHORS Motzkau M, et al.
TITLE Prospective and randomised evaluation of the protease-modulating effect of oxidised regenerated cellulose /collagen matrix treatment in pressure sore ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2015
AUTHORS Smeets, et al.
TITLE Effect of oxidized regenerated cellulose/collagen matrix on proteases in wound exudate of patients with diabetic foot ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Ulrich, et al.
TITLE Some effects of a topical collagen-based matrix on the microcirculation and wound healing in patients with chronic venous leg ulcers: preliminary observations
View Abstract on PubMed
STUDY TYPE All levels
DATE 2005
AUTHORS Wollina U, et al.
TITLE The role of oxidized regenerated cellulose / collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Hart, et al.
TITLE Randomized controlled trial on collagen/oxidized regenerated cellulose/silver treatment.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2013
AUTHORS Gottrup F, et al.
TITLE Randomized comparative trial of a collagen/oxidized regenerated cellulose dressing in the treatment of neuropathic diabetic foot ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Lazaro-Martinez, et al.
TITLE Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Kakagia DD, et al. 
TITLE Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Cullen B, et al.
TITLE The benefits of oxidized regenerated cellulose (ORC) for wound healing
View Abstract on PubMed
STUDY TYPE All levels
DATE 2010
AUTHORS Cullen B, et al.
TITLE Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate of patients with chronic venous ulceration
View Abstract on PubMed
STUDY TYPE All levels
DATE 2008
AUTHORS Smeets, et al.
TITLE A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers.
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Veves A, et al.
TITLE Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries
View Abstract on PubMed
STUDY TYPE All levels
DATE 2002
AUTHORS Ghatnekar O, et al.
TITLE Modulation of the chronic wound environment; an in vitro evaluation of advanced wound therapies
View Abstract on PubMed
STUDY TYPE All levels
DATE 2007
AUTHORS Cullen B, et al.

 

Ordering

To order any of the products listed below, please contact your KCI representative or call your local KCI Office. Click here to view our locations.

Contact Us

  • PROMOGRAN™ Matrix

    PRODUCT PRODUCT CODE   dressings per box
     
    FS-380x380-actisorb-silver-front.jpg

    PROMOGRAN™ Matrix

    28cm Hexagon

     
     
     M772028  10
     
    FS-380x380-actisorb-silver-front.jpg

    PROMOGRAN™ Matrix

    19.3cm Hexagon


     M772123  10